Gilead Sciences Inc (GILD)

77.99
0.18 0.23
NASDAQ : Health Care
Prev Close 78.17
Open 78.05
Day Low/High 77.80 / 78.39
52 Wk Low/High 77.63 / 113.31
Volume 3.20M
Avg Volume 10.15M
Exchange NASDAQ
Shares Outstanding 1.32B
Market Cap 105.27B
EPS 12.40
P/E Ratio 7.03
Div & Yield 1.88 (2.40%)

Latest News

'Mad Money' Lightning Round: I Can't Recommend Gilead

'Mad Money' Lightning Round: I Can't Recommend Gilead

Cramer says CyberArk Software is doing well but he's avoiding Clovis Oncology.

Jim Cramer's 'Mad Money' Recap: Markets Make This Economy, Not the Fed

Jim Cramer's 'Mad Money' Recap: Markets Make This Economy, Not the Fed

Cramer says he doesn't understand the obsession some investors have with the Federal Reserve. Forget the Fed.

Gilead Sciences Shares Slide on Leerink Price Target Cut

Gilead Sciences Shares Slide on Leerink Price Target Cut

Shares of Gilead Sciences were lower Wednesday after Leerink cut its price target on the shares.

Gilead (GILD) Price Target Cut Amid Weak Outlook for HIV Drug Sales

Gilead (GILD) Price Target Cut Amid Weak Outlook for HIV Drug Sales

Leerink trimmed its price target on Gilead Sciences (GILD) stock today as it anticipates lower revenue from HIV sales in the future.

Kelly A. Kramer Joins Gilead Sciences' Board Of Directors

Kelly A. Kramer Joins Gilead Sciences' Board Of Directors

Gilead Sciences, Inc. (Nasdaq:GILD) announced today that Kelly A.

Medivation Scores Premium in Sale to Pfizer

Medivation Scores Premium in Sale to Pfizer

Shareholders of the oncology drug maker ought to be satisfied with the auction's conclusion.

European Commission Grants Marketing Authorization For Gilead's Once-Daily Truvada® For Reducing The Risk Of Sexually Acquired HIV-1

European Commission Grants Marketing Authorization For Gilead's Once-Daily Truvada® For Reducing The Risk Of Sexually Acquired HIV-1

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted marketing authorization for once-daily Truvada ® (emtricitabine 200 mg/tenofovir disoproxil 245 mg; FTC/TDF) in combination...

Pfizer Is Buying Medivation for $14 Billion

Pfizer Is Buying Medivation for $14 Billion

Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.

Gilead Sciences (GILD) Stock Up, Piper Jaffray: Splitting Is 'Poor Idea'

Gilead Sciences (GILD) Stock Up, Piper Jaffray: Splitting Is 'Poor Idea'

Analysts at Piper Jaffray said in a note this morning that Gilead Sciences (GILD) can create value without splitting its HIV and HCV franchises.

Gilead May Be Better Off Splitting Itself in Two, Analysts Say

Gilead May Be Better Off Splitting Itself in Two, Analysts Say

A recent note from RBC Capital on Gilead gained a lot of attention as well as a pickup in call-option purchases.

S&P Isn't My Favorite Subject

A breakout is hard to come by.

Gilead (GILD) Stock Lower, Piper Jaffray: Little Required to 'Driver Shares Higher'

Gilead (GILD) Stock Lower, Piper Jaffray: Little Required to 'Driver Shares Higher'

Piper Jaffray analysts say Gilead Sciences (GILD) could be moving toward a 'modest' multiple.

Weekly Roundup: Why Current Valuations Make Little Sense

Big gainers last week, and a roundup of portfolio changes.

How Will Gilead (GILD) Stock React to Hepatitis-C Drug Prescriptions?

How Will Gilead (GILD) Stock React to Hepatitis-C Drug Prescriptions?

Prescription data for Gilead's (GILD) hepatitis-C treatments were mixed for the week ended August 5, according to Leerink.

Should Gilead Split in Two?

Should Gilead Split in Two?

RBC Capital analysts say this would free 'trapped value' on drug treatments.

Trade Idea: Time to Get Long Gilead

We think this is a ridiculously cheap stock.

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.

Gilead (GILD) Stock Slumps, Leerink: Drug Success Overshadowed By Sales Decline

Gilead (GILD) Stock Slumps, Leerink: Drug Success Overshadowed By Sales Decline

Leerink analysts said Gilead's (GILD) sales decline could be the result of several factors.

Watch Gilead for Buying Opportunities

Watch Gilead for Buying Opportunities

There is a case for a low already being in place.

CMCSA, IDXX, ZTS: Jim Cramer's Views

CMCSA, IDXX, ZTS: Jim Cramer's Views

Cramer shares his views on the winners and losers of this earnings season. Comcast, Idexx Laboratories and Zoetis are among the stocks discussed.

Gilead and Teva: Off-the-Charts Cheap

Gilead and Teva: Off-the-Charts Cheap

Rarely do investors get to buy these types of quality businesses at such discounted prices.

Cramer: Here's What to Embrace and What to Shun

Cramer: Here's What to Embrace and What to Shun

With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.

Biotech Pop-Up Party in Full Swing

Biotech Pop-Up Party in Full Swing

The beaten-down biotech sector is making an impressive comeback. The sector seems to be rebounding after tumbling by more than 40%.

It's 'All Systems Go' for Biotech

It's 'All Systems Go' for Biotech

The sector seems to be rebounding after tumbling by more than 40%.

3 Stocks Raising The Drugs Industry Higher

3 Stocks Raising The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the health services industry higher today.

Could a Spin-off of its Hepatitis C Division be in Gilead's Future?

Could a Spin-off of its Hepatitis C Division be in Gilead's Future?

The company also could look to acquire a smaller biotech company, though likely not Medivation.